REQUITE database and biobank Add to Contact List

The REQUITE project was an EU-funded, prospective, observational study which ran from 2013-18 (Seibold et al 2019). Manchester University was the research sponsor, with primary ethics approval given by the North West England REC with IRAS project ID 143488 and REC reference: 14/NW/0035, with secondary ethics approvals in other countries. REQUITE’s aim was to collect blood samples and clinical data from cancer patients treated with radiotherapy with curative intent, with the primary objective being to find factors affecting risk for radiotherapy side effects. Patient recruitment took place between April 2014 and March 2017 in 26 hospitals in eight countries (UK, Germany, France, Italy, Spain, Belgium, USA and Netherlands). Two UK centres were included as hubs in the project: Manchester and Leicester, with some patients also recruited in satellite hospitals in Nottingham, Derby and Salford. The study recruited 2071 breast, 1808 prostate and 561 lung cancer patients. Clinical data was collected using standardised data collection forms pre-radiotherapy, after-radiotherapy and at one- and two-years’ time-points post treatment. Both clinician and patient reported radiotherapy side effect data was collected. Blood samples were drawn pre-treatment only. Radiotherapy planning CT scans (DICOM files), organ dose-volume histograms and breast photographs were stored. At the current time the biological sample collection for the REQUITE cohort held at the University of Leicester consists of:  866 blood samples collected in PAXgene RNA tubes (2.5ml of blood + 6.9ml preservative)  4438 DNA samples (normalised concentration at 100ng/µl, volume 48-590µl)  4419 DNA samples (variable concentration stocks, volume 8-1000 µl) The content of the database consists of records for a total of 4438 radiotherapy patients, of which 2069 are breast cancer, 1808 prostate cancer and 561 lung cancer patients. The data held includes baseline information on:  Cancer treatment o Surgery type o Chemotherapy regimen o Radiotherapy technique o Total radiation dose and fractionation  Technical medical physics data o Radiotherapy planning CT scans saved as DICOM files (regional scans i.e. thoracic for breast & lung cancer patients, abdominal for prostate cancer) o 3D radiation dose distribution saved as RTPlan file o Organ delineations on CT scan saved as RTDose and RTStruct files o Dose-volume histograms for each organ-at-risk (these quantify the volume of each organ exposed to particular doses of radiation) And multiple time-point (for all patients pre-radiotherapy, 3 weeks and 1 year post radiotherapy, for breast and prostate patients also at 2 years, and on a sub-set of patients to 6 years after treatment) data for:  Medical (e.g. age, comorbidities, BMI, prescription medications)  Physician reported radiotherapy side effects (CTCAE v4.0)  Patient reported radiotherapy side effects  Quality of life questionnaire Laboratory data that was generated during the REQUITE project is also held in the database:  Imputed SNP genotype data on 4409 patients  Radiation-induced lymphocyte apoptosis assay data on 1319 patients (only patients recruited in Mannheim, Montpellier and Leicester)

Contact Information

Last Updated: 10/01/2024

Annual Statistics